MedTrace Logo

The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker

NCT03245996 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-07-10

No results posted yet for this study

Summary

This study is divided into two parts:

* The first part evaluates the acute effect of non-pharmacological heart rate change on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker
* The second part evaluates the acute effects of atenolol, nebivolol and ivabradine on central hemodynamic parameters noninvasively in sick sinus syndrome patients with a permanent cardiac pacemaker at different pacing rate levels

Conditions

  • Aortic Blood Pressure

Interventions

DEVICE

AAI 40 bpm

Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study

DEVICE

AAI 60 bpm

Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study

DEVICE

AAI 90 bpm

Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study

DRUG

Atenolol Pill

50 or 100 mg of atenolol is administered to subjects in the second part of the study

DRUG

Nebivolol Pill

5 mg of nebivolol is administered to subjects in the second part of the study

DRUG

Ivabradine Pill

5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study

Sponsors & Collaborators

  • Tartu University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-09-30
Completion
2016-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245996 on ClinicalTrials.gov